To develop and deliver innovative treatment of brain disease, we work with a range of stakeholders. These include healthcare professionals, patients and their respective organizations. We collaborate on research, clinical development, exchange of scientific information, and marketing and sales activities.
These interactions are well-regulated by the national laws and industry association regulations that we integrate into our working processes, training and guidance.
We are committed to transparency and our disclosed information follows the current laws or regulations from the industry associations we have joined, such as the European Federation of Pharmaceutical Industries and Associations (EFPIA).
According to the Ethical rules for dialogue and negotiations with decision-makers published by Danish Ethical Committee for the Pharmaceutical Industry, every pharmaceutical company is obliged to publish a schedule on their website with the names of the PR or communication agencies, legal counsel or similar external consultancies acting on behalf of the pharmaceutical company to engage in dialogue and negotiations with decision-makers.
The following external consultants are representing H. Lundbeck A/S in dialogue and negotiation with decision makers:
Rud Pedersen Public Affairs
Christians Brygge 24, 3.
DK- 1559 København V
Lead Agency
Ravnsborg Tværggade 5c, 1.
DK-2200 København N
We have made the external agencies aware of the present set of rules and that the pharmaceutical company accepts responsibility for ensuring third party compliance therewith.
Here you can find an overview, together with the locations, of Lundbeck’s interactions with healthcare professionals and the related transfers of value:
Lundbeck discloses payments and other transfers for value to HCPs and HCOs in aggregate, if the HCP or HCO has used their legal right to refuse consent to individual disclosure, in accordance with the EFPIA Disclosure Code. The data covers Lundbeck affiliates that use Lundbeck’s corporate website for disclosure. Data from other countries can be found on the Country overview tab.
EFPIA aggregate disclosures on this site include data from the following countries and the tables are organized according to EFPIA specifications:
Event Sponsorships | Consultancies (Fee for Service) | |||
Aggregate HCPs | Registration fees | Travel & Accomodation | Fees | Related expenses |
Number and % of non-disclosed HCPs | 0 | 4 (3%) | 0 | 0 |
Amount and % related to non-disclosed HCPs | €0 | €329 (1%) | €0 | €0 |
All Bulgarian HCOs have consented to disclosure.
Event Sponsorships | Consultancies (Fee for Service) | |||
Aggregate HCPs | Registration fees | Travel & Accomodation | Fees | Related expenses |
Number and % of non-disclosed HCPs | 0 | 0 | 12 (15%) | 0 |
Amount and % related to non-disclosed HCPs | €0 | €0 | €4,035.05 (13%) | €0 |
All Croatian HCOs have consented to disclosure.
All Estonian HCPs have consented to disclosure.
All Estonian HCOs have consented to disclosure.
Event Sponsorships | Consultancies (Fee for Service) | |||
Aggregate HCPs | Registration fees | Travel & Accomodation | Fees | Related expenses |
Number and % of non-disclosed HCPs | 223 (67%) | 108 (71%) | 0 | 0 |
Amount and % related to non-disclosed HCPs | €39,900 (76%) | €50,248 (78%) | €0 | €0 |
Event Sponsorships | Consultancies (Fee for Service) | |||||
Aggregate HCOs | Donations & Grants |
Sponsorship of HCO | Registration fees | Travel & Accomm. | Fees | Related expenses |
Number and % of non-disclosed HCOs | 0 | 5 (100%) | 0 | 0 | 7 (78%) | 0 |
Amount and % related to non-disclosed HCOs | €0 | €5,134 (100%) | €0 | €0 | €40,090 (88%) | €0 |
All Latvian HCPs have consented to disclosure.
All Latvian HCOs have consented to disclosure.
Event Sponsorships | Consultancies (Fee for Service) | |||
Aggregate HCPs | Registration fees | Travel & Accomodation | Fees | Related expenses |
Number and % of non-disclosed HCPs | 1 (6%) | 4 (11%) | 0 | 0 |
Amount and % related to non-disclosed HCPs | €715 (5%) | €2,538 (3%) | €0 | €0 |
All Lithuania HCOs have consented to disclosure.
Event Sponsorships | Consultancies (Fee for Service) | |||
Aggregate HCPs | Registration fees | Travel & Accomodation | Fees | Related expenses |
Number and % of non-disclosed HCPs | 7 (58%) | 0 | 7 (20%) | 10 (33%) |
Amount and % related to non-disclosed HCPs | €3,459 (65%) | €0 | €1,210 (9%) | €16,147 (53%) |
Event Sponsorships | Consultancies (Fee for Service) | |||||
Aggregate HCOs | Donations & Grants |
Sponsorship of HCO | Registration fees | Travel & Accomm. | Fees | Related expenses |
Number and % of non-disclosed HCOs | 2 (100%) | 0 | 0 | 0 | 0 | 0 |
Amount and % related to non-disclosed HCOs | €30,641 (100%) | €0 | €0 | €0 | €0 | €0 |
Lundbeck undertakes research activities and conducts clinical studies globally. Clinical studies are conducted in accordance with international guidelines and performed by HCPs and HCOs. Our payments and other transfers of value related to pre-clinical, clinical and non-interventional studies are disclosed in aggregate.
Country | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
Bulgaria | €319,234 | €661,840 | €1,349,624 | €961,636 | €745,539 | €403,565 |
Croatia | 303,693 HRK | €24,431 | €295 | €720 | €5,101 | - |
Estonia | - | €492,586 | €235,171 | - |
- |
- |
Hungary | €30,128 | €107,946 | €52,271 | €35,647 | €52,343 | €46,635 |
Latvia | €83,105 | €199,889 | €164,272 | - |
- |
- |
Lithuania | €229,952 | €77,033 | - | - |
- |
- |
Ukraine | €359,207 | €99,857 | €452,015 | €267,937 | €413,939 | €232,245 |
The amounts cover payments and other transfers of value to HCPs and HCOs related to pre-clinical, clinical and non-interventional studies in the countries where the Lundbeck affiliate uses Lundbeck’s corporate website for disclosure in accordance with the EFPIA Disclosure Code.
Data from other countries can be found under Countries that disclose.
We pursue our business purpose guided by several pillars and our Code of Conduct.
Our policy for scientific publications and responsible clinical data sharing.
We see patients as people and are committed to support the person behind.